難治性便秘の評価と管理に関するAGA臨床診療アップデート：専門家レビュー
Kyle Staller1, Leila Neshatian2, Anthony Lembo3
1Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts.
まとめ
難治性便秘（RC）では、二次的な原因を除外し、結腸通過遅延を確認する必要があります。重度のRCに対する手術は選択肢ですが、潜在的なリスクと結果のため、慎重な評価が必要です。
背景:
- 一部の患者は、医学的治療にもかかわらず難治性便秘（RC）を経験し、診断と治療の課題を提示します。
- RCは比較的まれであり、診断と管理への体系的なアプローチが必要です。
結論:
- RCに対する外科的治療は、リスクと満足のいく結果が得られない可能性があり、徹底的な術前評価が必要です。
- 手術への適合性を評価し、結果を予測するために心理学的評価が推奨されます。
- 回腸直腸吻合を伴う結腸切除術は、進行中の排便障害のない患者に限定されるべきです。
関連する概念動画
01:21Drugs for Treatment of Constipation-Predominant IBS
698
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698
01:30Irritable Bowel Syndrome III: Medical and Nursing Management
638
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
638
01:30Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
727
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
727
01:17Drugs for Treatment of Diarrhea-Predominant IBS
618
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
618
01:17Chronic Bowel Disorders: Introduction
743
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
743
01:29Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471